This study is currently not recruiting participants.

MICROBE 0 - Microbiotics In Recurrent Clostridium difficile infection: Restoration Of Bacteria: An Investigator-Initiated Open Label Study to Evaluate the Tolerability Safety and Efficacy of FIN-403 in the Prevention of Recurrent CDI

Study on Investigational Medication for Recurrent Clostridium Difficile Infection (CDI)

Not Recruiting
100 years or below
All
Phase N/A

Brief description of study.

The purpose of this study is to evaluate the short-term safety of FIN-403 in patients with recurrent Clostridium difficile infection (CDI); to evaluate how well FIN-403 works in patients with recurrent CDI; to evaluate time to CDI recurrence after taking FIN-403; and to assess the impact of FIN-403 on quality of life.

Detailed description of study

The purpose of this study is to evaluate the short-term safety of FIN-403 in patients with recurrent Clostridium difficile infection (CDI); to evaluate how well FIN-403 works in patients with recurrent CDI; to evaluate time to CDI recurrence after taking FIN-403; and to assess the impact of FIN-403 on quality of life.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Clostridium difficile infection
  • Age: 100 years or below
  • Gender: All

This study investigates the effects of an investigational medication on recurrent Clostridium difficile infection (CDI). Clostridium difficile is a type of bacteria that can cause severe diarrhea and other intestinal issues. The study aims to understand the safety of the investigational medication and how well it works in preventing the recurrence of CDI.

Participants in this study will receive either the investigational medication or a placebo. A placebo is an inactive substance that looks like the investigational medication but does not contain any medicine. The study will monitor the time it takes for CDI to recur, if at all, and assess the participants' quality of life during the study.

  • Who can participate: Participants must be adults aged 18 and older with a history of recurrent Clostridium difficile infection. Additional eligibility criteria may apply.
  • Study details: Participants will take either the investigational medication or a placebo. The study will monitor their health and any recurrence of CDI.
Updated on 19 Feb 2024. Study ID: 1707399087

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the study team